OSIMERTINIB for Prophylaxis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 17 adverse event reports in the FDA FAERS database where OSIMERTINIB was used for Prophylaxis.
Most Reported Side Effects for OSIMERTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 10,423 | 37.6% | 10,418 | 239 |
| Malignant neoplasm progression | 2,920 | 10.5% | 574 | 354 |
| Diarrhoea | 1,408 | 5.1% | 174 | 431 |
| Drug resistance | 1,026 | 3.7% | 139 | 98 |
| Fatigue | 819 | 3.0% | 102 | 231 |
| Rash | 772 | 2.8% | 79 | 212 |
| Decreased appetite | 706 | 2.5% | 138 | 273 |
| Drug ineffective | 627 | 2.3% | 144 | 111 |
| Dyspnoea | 621 | 2.2% | 158 | 327 |
| Nausea | 610 | 2.2% | 82 | 228 |
| Disease progression | 607 | 2.2% | 107 | 33 |
| Off label use | 576 | 2.1% | 115 | 124 |
| Interstitial lung disease | 573 | 2.1% | 221 | 305 |
| Metastases to central nervous system | 560 | 2.0% | 125 | 109 |
| Myelosuppression | 510 | 1.8% | 10 | 166 |
Other Indications for OSIMERTINIB
Non-small cell lung cancer (6,358)
Lung neoplasm malignant (4,754)
Lung carcinoma cell type unspecified stage 0 (1,950)
Non-small cell lung cancer metastatic (1,056)
Lung adenocarcinoma (936)
Egfr gene mutation (695)
Product used for unknown indication (408)
Non-small cell lung cancer stage iv (404)
Neoplasm malignant (345)
Lung carcinoma cell type unspecified stage iv (330)
Other Drugs Used for Prophylaxis
PEGFILGRASTIM (7,424)
HUMAN C1-ESTERASE INHIBITOR (5,950)
DENOSUMAB (4,541)
SULFAMETHOXAZOLE\TRIMETHOPRIM (3,197)
ASPIRIN (2,083)
VALACYCLOVIR (1,574)
PANTOPRAZOLE (1,502)
VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN (1,444)
CLOPIDOGREL BISULFATE (1,296)
ENOXAPARIN (1,278)